PharmaLedger #3 Open Webinar | Making ePI a Reality | Full Recording
In this #3 Open Webinar | Making ePI a Reality presentation, you will find:
Our third open webinar is first moderated by PharmaLedger’s Culture and Adoption Team Member Martin Hunt (Onorach) and has a brief introduction of the project by GSK’s Representative for the ePI use case Paul Marley (GlaxoSmithKline).
Our third open webinar is first moderated by PharmaLedger’s Culture and Adoption Team Member Martin Hunt (Onorach) and has a brief introduction of the project by GSK’s Representative for the ePI use case Paul Marley (GlaxoSmithKline).
Topic 1. ePI Journey
The ePI use case is introduced by PharmaLedger’s ePI Co-Lead Ken Thursby (MSD).
Topic 2. Healthcare Professional Focus Group Discussion (HCP FGD)
The second presentation was led by PharmaLedger’s ePI Use Case Proof-of-Concept Co-Lead Tarn Yeong (TY) Goh (MSD), who talked about the Singapore Healthcare Professional (HCP) Focus Group from August 2021.
Topic 3. Interview with the Patients
The third presentation was led by PharmaLedger’s partner, the European Patient’s Forum Project Coordinator Hannes Jarke (EPF), who moderated three patient speakers that participated in a project involving the ePI app. The three patients that shared their experience are Silvia Scalabrini, Marta Morato and Robert Joyce.
Topic 4. Demo of the App
A live demo of the ePI mobile application was presented by Sonja Steiner (Novartis), who works with the ePI and Anti-Counterfeiting use cases. She provided a demo of the ePI mobile application.
Topic 5. ePI Future State
The final presentation was conducted by PharmaLedger’s ePI Use Case Co-Lead Patrick Maher (Novartis), who highlighted the next development steps, aims and milestones of the ePI use case.
6. Live Q&A
PharmaLedger’s Culture and Adoption Team Member Martin Hunt (Onorach) presented the questions ([1:10:27] timestamp) that were asked by the audience from both webinar sessions. The recording of the Q&A is included, where the presenters answered these questions.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853992. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
Disclaimer: Any information on this presentation solely reflects the author’s view and neither IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained herein.